Summary
Indian drugmakers are opposing a proposal that would make them solely responsible for medicine overpricing, arguing it unfairly exempts retail chemists, hospitals, and nursing homes. Pharmaceutical groups believe accountability should extend to all parties involved in setting the final patient price.